Lonvoguran ziclumeran (lonvo-z)

Name: Lonvoguran ziclumeran (lonvo-z) in Hereditary angioedema: Pathophysiology
Published: 2026-09-14T15:39:06-04:00

Hereditary angioedema

Also known as NTLA-2002

Manufacturer: Intellia Therapeutics
Regulatory submission: Rolling BLA initiated April 2026 and accepted September 2026
Launch: Anticipated in the first half of 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description

Pathophysiology

1 evidence topic · 1 source

Pathophysiology

“Hereditary angioedema (HAE) is characterized by C1 esterase inhibitor (C1INH) deficiency, leading to uninhibited kallikrein-kinin system (KKS) activation and bradykinin production resulting in angioedema attacks” (opens the source at this quote in a new tab)